Advertisement

Search Results

Advertisement



Your search for Blood matches 4802 pages

Showing 601 - 650


cost of care
legislation

Ibrutinib Included Among the 10 Drugs Slated for Medicare Price Negotiations

On August 29, the Biden Administration announced the first 10 prescription medications that will be included in Medicare’s price negotiations with drug manufacturers as the government aims to reduce the financial burden on millions of older Americans and potentially save the Medicare program...

myelodysplastic syndromes

FDA Approves Luspatercept-aamt as First-Line Treatment for Adult Patients With Lower-Risk MDS and Anemia Who May Require Transfusions

On August 28, the U.S. Food and Drug Administration (FDA) approved luspatercept-aamt (Reblozyl) to treat anemia in adult patients with very low– to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell transfusions and who have not received previous...

solid tumors
supportive care

Cardiorespiratory Fitness in Youth May Be Associated With a Lower Risk of Nine Cancer Types

Partaking in cardiorespiratory fitness in youth may be associated with up to a 40% lower risk of developing nine cancer types later in life, according to a recent study published by Onerup et al in the British Journal of Sports Medicine. Background Cardiorespiratory fitness—including sustained...

lung cancer

Addition of Neoadjuvant Monoclonal Antibody to Platinum-Based Chemotherapy in Resectable NSCLC

In a Chinese phase II trial (TD-FOREKNOW) reported in JAMA Oncology, Lei et al found that the addition of neoadjuvant camrelizumab to platinum-based chemotherapy resulted in a higher pathologic complete response rate among patients with resectable stage IIIA or IIIB (T3N2) non–small cell lung...

solid tumors

Noninvasive, Multitarget Stool DNA Methylation Assay Under Study in Early Detection of Multiple Gastrointestinal Cancers

A prospective study in China found that a noninvasive, multitarget stool DNA methylation assay was accurate in the early detection and identification of the tissue of origin of gastrointestinal cancers.1 The study, conducted by Li-Yue Sun, MD, of Guangdong Second Provincial General Hospital,...

solid tumors

Liquid Biopsy Assay Demonstrated Effectiveness in Early Cancer Detection in Asymptomatic Individuals in Vietnam

A Vietnamese prospective study by Hanh Thi-Hue Nguyen, BS, and Le Son Tran, PhD, both of the Medical Genetics Institute and Gene Solutions, Ho Chi Minh City, Vietnam, and colleagues, investigating the feasibility and performance of a circulating tumor DNA (ctDNA) analyzing test in the early...

myelodysplastic syndromes
hematologic malignancies
issues in oncology

Do MDS Diagnoses Require Second Opinions?

Investigators have identified a need for strong coordination between clinicians and skilled pathologists to ensure accurate, timely diagnosis of myelodysplastic syndromes (MDS). The study findings were recently published by Gorak et al in Blood Advances. Background MDS—a collection of chronic...

prostate cancer
issues in oncology

Four Novel Biomarkers May Help Detect Black Patients at Risk of Advanced Prostate Cancer

Researchers have identified a cell metabolism process found in male patients with West African ancestry who have diabetes and metastatic prostate cancer that could potentially lead to improved testing and treatments for Black patients with both diseases. The findings by Shuck et al were presented...

lymphoma
cardio-oncology

Effect of Atorvastatin on Cardiac Dysfunction in Patients Receiving Anthracyclines for Lymphoma

In a study (STOP-CA) reported in JAMA, Neilan et al found that atorvastatin reduced the risk of decreased left ventricular ejection fraction (LVEF) in patients receiving anthracycline-based chemotherapy for the treatment of lymphoma. Study Details In the U.S.-Canadian double-blind trial, 300...

bladder cancer
kidney cancer
prostate cancer

Genitourinary Oncology 2023 Almanac

It is an exciting time in the development of new treatments for urologic cancers. There have been a number of major changes both in advanced disease and in the perioperative setting over the past year. Urothelial and Bladder Cancers In urothelial cancer, at last, we have randomized data supporting...

skin cancer

FDA Approves Melphalan Hepatic Delivery System for Adult Patients With Unresectable Hepatic-Dominant Metastatic Uveal Melanoma

On August 14, the U.S. Food and Drug Administration (FDA) approved the HEPZATO KIT, a melphalan hepatic delivery system, as a liver-directed treatment for adult patients with metastatic uveal melanoma and unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic...

multiple myeloma

Accelerated Approval for Elranatamab-bcmm in Patients With Relapsed or Refractory Multiple Myeloma

On August 14, the U.S. Food and Drug Administration (FDA) granted accelerated approval to elranatamab-bcmm (Elrexfio), a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adult patients with relapsed or refractory multiple myeloma who have received at least four prior...

Expert Point of View: Ajay K. Nooka, MD, MPH

Insights on findings from the phase II MonumenTAL-1 trial1 were offered by Ajay K. Nooka, MD, MPH, Professor in the Department of Hematology and Medical Oncology, and Medical Director of the Winship Data and Technology Applications Shared Resource, Winship Cancer Institute, Emory University School ...

Expert Point of View: Ciara L. Freeman, MD, PhD and Asher Chanan-Khan, MD

Ciara L. Freeman, MD, PhD, Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, was impressed with the CARTITUDE-4 findings. She said “treaters and patients” will be “watching this space” to see how the results change the...

leukemia
immunotherapy

Blinatumomab Improves Survival in MRD-Negative, B-Cell ALL

The standard of care could be changing for adults with newly diagnosed BCR-ABL–negative B-lineage acute lymphoblastic leukemia (ALL) who achieve measurable residual disease (MRD) negativity after induction chemotherapy. In the phase III E1910 trial by the ECOG-ACRIN Cancer Research Group, an...

hematologic malignancies

Hematologic Oncology 2023 Almanac

The past several months have brought significant advances within the field of hematologic oncology. Here we will review some key updates focusing on pivotal clinical trials and new drug approvals. Advances in Lymphoma Presented at the 2023 ASCO Annual Meeting, SWOG S1826 compared nivolumab plus...

prostate cancer
genomics/genetics

FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

On August 11, the U.S. Food and Drug Administration (FDA) approved the fixed-dose combination of niraparib and abiraterone acetate (Akeega), with prednisone, for adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer, as determined by...

cost of care

Overcoming Financial Toxicity From Cancer

I knew the moment my fingers found a lump in my left breast, in 2018, that it was cancer, and I wondered if I was going to die. My maternal grandmother had been diagnosed with breast cancer when she was 39, the same age I was when I discovered the mass in my breast. She died 5 years later. Divorced ...

hematologic malignancies
immunotherapy

CAR T-Cell Therapies: Trends and Indications

The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. With this installment, we launch a new series of articles on commercially available chimeric antigen receptor (CAR) T-cell therapies. Syed Ali Abutalib, MD, and Jennifer N. ...

prostate cancer

Talazoparib With Enzalutamide in HRR Gene–Mutated Metastatic Castration-Resistant Prostate Cancer

On June 20, 2023, the PARP inhibitor talazoparib was approved for use with enzalutamide in homologous recombination repair (HRR) gene–mutated metastatic castration-resistant prostate cancer.1 Supporting Efficacy Data Approval was based on findings in the multicohort, double-blind TALAPRO-2 trial...

survivorship
cardio-oncology

How Multidisciplinary Specialties Are Coming Together to Improve the Quality of Life of Cancer Survivors

As we detailed in our Special Report “Surviving, but Not Always Thriving, After Cancer,” in the May 25, 2023, issue of The ASCO Post, the combination of advances in more effective therapies to treat cancer, gains in early detection, and sharp declines in tobacco use have led to a staggering 33%...

colorectal cancer

Report Highlights Rapid Adoption of Clinical Research Results Into Colon Cancer Chemotherapy Prescribing Patterns

New research published by Ou et al in JNCCN—Journal of the National Comprehensive Cancer Network evaluated how an important analysis on adjuvant chemotherapy for advanced colon cancer impacted prescribing patterns. The IDEA collaboration included more than 12,000 patients with stage III colon...

breast cancer

How Does BMI Affect Cardiac Health for Patients With Breast Cancer Receiving Chemotherapy?

A study covering the northeast region of Colombia found nearly 12% of patients with a high body mass index (BMI) being treated for breast cancer at a regional center experienced cardiotoxicity during chemotherapy. The study will be presented at the upcoming American College of Cardiology Latin...

head and neck cancer

EBV-Based Screening Methods for Identifying Nasopharyngeal Carcinoma

In a Taiwanese study reported in the Journal of Clinical Oncology, Lou et al compared two methods of Epstein-Barr virus (EBV) screening to identify nasopharyngeal carcinoma. Study Details Blood samples were obtained from 819 incident Taiwanese nasopharyngeal carcinoma cases (including 213 cases of...

leukemia

Outcomes in Children and Young Adults With T-Cell ALL and Induction Failure in Contemporary Treatment Trials

In a retrospective study reported in the Journal of Clinical Oncology, Elizabeth A. Raetz, MD, and colleagues found that outcomes in children and young adults with T-cell acute lymphoblastic leukemia (ALL) who do not achieve remission at the end of induction therapy have improved in contemporary...

colorectal cancer
issues in oncology

ACP Issues Updated Clinical Guidelines for Screening Asymptomatic, Average-Risk Adults for Colorectal Cancer

The American College of Physicians (ACP) suggested screening asymptomatic, average-risk adults for colorectal cancer at age 50 years, according to updated clinical guidelines published by Qaseem et al in the Annals of Internal Medicine. New ACP Clinical Guidelines Colorectal cancer has the fourth...

immunotherapy
issues in oncology

Researchers Characterize Adverse Immune Events in Patients With Cancer Who Experience Immune Checkpoint Inhibitor–Associated Arthritis

Researchers may have uncovered the immune adverse events and the specific type of CD8 T cells that characterize inflammatory arthritis induced by immune checkpoint inhibitors, according to a recent study published by Wang et al in Science Immunology. Immune checkpoint inhibitors used to treat...

gastrointestinal cancer

Noninvasive Multitarget Stool DNA Methylation Assay in the Early Detection of Multiple Gastrointestinal Cancers

With an estimated 4.8 million new cases and 3.4 million deaths worldwide recorded in 2018, cancers of the gastrointestinal tract account for over one-quarter (26%) of global cancer incidence and over one-third (35%) of all cancer-related deaths. Although the U.S. Food and Drug Administration (FDA)...

issues in oncology

Liquid Biopsy Assay Demonstrates Effective Early Cancer Detection in Asymptomatic Individuals in Vietnam

Studies show that both the incidence of cancer and mortality rates in Vietnam have tripled over the past 3 decades; in 2020, over 182,560 new cases of cancer were diagnosed in the country, and nearly 123,000 people died from the disease. In addition, most cases—up to 80%—are diagnosed at an...

myelodysplastic syndromes

Expert Point of View: Anand Ashwin Patel, MD

As presented at the 2023 ASCO Annual Meeting, the phase III IMerge trial of imetelstat1 and the phase III ­COMMANDS trial of luspatercept2 met their primary endpoints of transfusion independence. The findings suggest that lower-risk patients with transfusion-dependent, non-del(5q) myelodysplastic...

myelodysplastic syndromes

IMerge Trial: Use of Imetelstat Reduces Transfusion Dependence in Lower-Risk MDS

In the primary analysis of the phase III randomized, double-blind, placebo-controlled IMerge trial, in those achieving the primary endpoint of 8-week transfusion independence, treatment with imetelstat significantly reduced transfusion dependence—for a median duration of 1 year—and improved a...

colorectal cancer
issues in oncology

Patients in Lower-Income Communities May Be Less Likely to Receive CT Colonography Than Those in Higher-Income Communities

Patients who reside in lower-income communities may be less likely to undergo colorectal cancer screenings with computed tomography (CT) colonography than those who reside in higher-income communities, according to a new study published by Christensen et al in the American Journal of ...

colorectal cancer

Reasons for Nonparticipation in a Colorectal Cancer Screening Trial Comparing Outcomes With Colonoscopy vs FIT

In an analysis reported in JAMA Network Open, Robertson et al found U.S. veterans most frequently cited a preference for stool testing as a reason for declining participation in the CONFIRM trial, which compared the effect on colorectal cancer mortality with annual colonoscopy vs annual fecal...

head and neck cancer

Investigators Evaluate the Effect of Body Mass Index on Outcomes in Patients With Head and Neck Cancer

Investigators reported that patients with head and neck cancer who had an overweight body mass index (BMI) may have had better outcomes, longer overall and progression-free survival, and lower rates of locoregional failure than those patients with a normal or obese BMI, according to a recent study...

breast cancer
issues in oncology

Biological Aging and Radiation Therapy for Breast Cancer

Some patients who have received treatment for breast cancer may experience increased biological aging compared with those who have never been diagnosed with breast cancer, according to a new study published by Kresovich et al in the Journal of the National Cancer Institute. The findings showed that ...

Damon Runyon Names Physician-Scientist Awardees

Three scientists who are researching novel approaches to the treatment of cancer have been named the 2023 recipients of the Damon Runyon Physician-Scientist Training Award: Nicole M. Cruz, MD; Mounica Vallurupalli, MD; and Nina Weichert-Leahey, MD. The awardees were selected through a highly...

integrative oncology

Berberine

The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Ting Bao, MD, DABMA, MS, and Jyothirmai Gubili, MS, focus on the use of...

leukemia

WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues

The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Syed Ali Abutalib and L. Jeffrey Medeiros explore the World Health Organization (WHO) classification of hematopoietic and lymphoid tissue...

gynecologic cancers

In Ovarian Cancer, Neoadjuvant Olaparib Feasible, Appears Effective in Pilot Study Among Patients With BRCA Mutation

Encouraging outcomes were achieved in patients with BRCA-mutated ovarian cancer who received neoadjuvant treatment with olaparib in a feasibility study led by Shannon N. Westin, MD, MPH, Professor in the Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD...

colorectal cancer
gynecologic cancers

MLH1 Methylation Status and Screenings for Colorectal or Endometrial Cancer

New research could warrant reconsideration of current screening guidelines to include a poorly recognized cause of Lynch syndrome, according to a novel study published by Hitchins et al in JNCCN–Journal of the National Comprehensive Cancer Network. The findings suggest that the guidelines leave a...

kidney cancer
supportive care

Incidence and Outcomes of Severe Hepatopathy in National Wilms Tumor Study Protocols

In an analysis of National Wilms Tumor Study (NWTS) protocols reported in the Journal of Clinical Oncology, Oosterom et al identified the incidence of treatment-related severe hepatopathy in patients with Wilms tumor and described outcomes in these patients. Study Details The study involved data...

hematologic malignancies
issues in oncology

New Tool May Help Physicians Pinpoint Gaps in Hematologic Malignancy Awareness

The novel Blood Cancer Awareness Measure tool could identify gaps in the public's knowledge of hematologic malignancy symptoms and aid in the development of future awareness campaigns designed to save lives, according to a new study published by Boswell et al in BMC Cancer and Whitaker et al in...

lung cancer

Prediction of Lung Cancer Mortality With Blood-Based Biomarker Panel and PLCO Risk Model

In a study reported in the Journal of Clinical Oncology, Irajizad et al found that use of a blood-based four-marker protein panel (4MP)—together with the Prostate, Lung, Colorectal, and Ovarian (PLCOm2012) lung cancer risk model—was capable of identifying patients at high risk of lung cancer...

leukemia
issues in oncology

Overweight and Obese BMI May Be Linked to Adverse Treatment Outcomes in AYA Patients With ALL

An elevated body mass index (BMI) could potentially be associated with inferior treatment outcomes in adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL), according to a new study published by Shimony et al in Blood Advances. The findings may demonstrate the impact of...

hematologic malignancies

Goals of Care in Primary Myelofibrosis

This is Part 3 of Updates in Myeloproliferative Neoplasms, a three-part video roundtable series.   In this video, Dr. Naveen Pemmaraju and Dr. Gabriela Hobbs discuss goals of care in primary myelofibrosis.   The patient is a 27-year-old woman who presents to the clinic after 6 months of...

breast cancer
supportive care

Targeting Depressive Symptoms in Younger Breast Cancer Survivors

Guest Editor’s Note: Psychological distress is highly prevalent in women diagnosed with premenopausal breast cancer and has a significant negative impact on their quality of life. Thus, effective strategies are urgently needed to reduce the symptom burden. In this installment of The ASCO Post’s...

solid tumors
issues in oncology

ASCO Updates Guideline on Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer

Results from a series of randomized, controlled trials have prompted an update to the ASCO guideline on venous thromboembolism (VTE) prophylaxis and treatment in patients with cancer. The revised guideline, which had last been updated in 2019, is available from the Journal of Clinical Oncology.1...

gastroesophageal cancer
immunotherapy

Addition of Tislelizumab to Chemotherapy Improves Survival in Treatment of Metastatic Esophageal Squamous Cell Carcinoma

As reported in The Lancet Oncology by Jianming Xu, MD, of Fifth Medical Center, Chinese PLA General Hospital, Beijing, corresponding author Harry H. Yoon, MD, of the Department of Oncology, Mayo Clinic, Rochester, and colleagues, an interim analysis of the phase III RATIONALE-306 trial has shown...

Expert Point of View: Ciara L. Freeman, MD, PhD and Asher Chanan-Khan, MD

Ciara L. Freeman, MD, PhD, Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, was impressed with the CARTITUDE-4 findings. She said “treaters and patients” will be “watching this space” to see how the results change the...

head and neck cancer
issues in oncology

Investigators Evaluate the Role of BMI in Outcomes in Patients With Head and Neck Cancer

Investigators have found that patients with head and neck cancer who had an overweight body mass index (BMI) may have had better outcomes, longer overall and progression-free survival, and lower rates of locoregional failure than those with a normal or obese BMI, according to a new study published...

Advertisement

Advertisement




Advertisement